CATALYSTSeekingAlpha • 1d ago
Teva: I Still See Upside After A Massive RallyTeva Pharmaceutical Industries is undergoing a strategic transformation, pivoting from generics to innovative biopharmaceuticals. Read more on TEVA here.
Why TEVA Stock surged +3.75% Today — RQD Quant Desk Flash
$41.47 +3.75% NYSE • Public Delayed / 60s Snapshot
Teva Pharmaceutical Industries Limited (TEVA) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (61/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+153.8% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
ROARABLE D+ • SELL / AVOID
Cap $48.32B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE+1.4% Base Target
WHALE OPTIONS TUG-OF-WAR:64% Call Buyers ($5.6M)
36% PutsMax Pain: $41.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TEVA Stock surged +3.75% Today — RQD Quant Desk Flash
Teva Pharmaceutical Industries Limited (TEVA) surged +3.75% to $41.47 as options desks priced 64% call premium vs. 36% put protection around the $41 max-pain magnet. Accounting Warning: Paper earnings outpaced operating cash flow (+153.8% (NI vs OCF)) as receivables rose.
- ▸Technical Tape: Trading at 95% of its 52-week range ($20.11 – $42.59) with RSI-14 at 63.7 (BULLISH MOMENTUM).
- ▸Whale Options Positioning: $5.6M in bullish call flow vs. $3.1M in put flow (Put/Call 0.56x, implied earnings swing ±6.9%).
- ▸Primary SEC / Cross-Feed Trigger: TEVA Accounting Gap: Net Income (+186%) Outpaced OCF (+32.2%) With +8% Working-Capital Build
Live TEVA Headlines & Catalysts
MARKET WIREYahoo • 1d ago
Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In DealmakingU.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week.
MARKET WIREYahoo • 1d ago
Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?Teva's pivot from generics to branded drugs has succeeded, but keep an eye out for this potential headwind.
CATALYSTSeekingAlpha • 1d ago
AbbVie: Why I See More Upside After Q3AbbVie posts strong Q3 growth, Skyrizi sales surge, and 2026 EPS guidance rises. Click for this ABBV earnings update.
CATALYSTYahoo • 2d ago
Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” MilestoneKey TakeawaysBausch Health jumped 21% after adjusted EPS of $1. 77 beat estimates, and it raised its outlook again.
MARKET WIREYahoo • 2d ago
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 EarningsGet a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates fo
MARKET WIREBenzinga • 4d ago
'Trump Administration Backs Down on an Opioid Ban After Kratom Industry Lobbying' - NY Timeshttps://www.nytimes.com/2026/10/28/us/politics/trump-opioid-kratom.html
RISK WATCHYahoo • 4d ago
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience PipelineBXCL501, a dexmedetomidine sublingual film, is under FDA review for first-ever at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adultsAcquisition adds differen
MARKET WIREBenzinga • 5d ago
Teva Pharmaceuticals International GmbH Acquires BioXcel Therapeutics' Assets For $57.5M Upfront PaymentTeva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that it has completed the acquisition of assets from BioXcel Therapeutics, Inc.,
MARKET WIRESeekingAlpha • 6d ago
Baron Health Care Fund Q3 2026 Top Contributors And DetractorsThe Baron Health Care Fund Q3 2026 report highlights key contributors and detractors from portfolio performance. Read the full analysis for more details.
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring TEVA)
- ✓Live walkthrough of TEVA's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
TEVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.02%📐 HORIZONTAL RANGE
2026-10-30O $41.17H $42.59L $41.17C $42.09VOL 7.36M
RES: $43.46SUP: $23.90SMA50: $39.08SMA200: $34.58
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TEVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
26.5%/yr Implied 5Y Growth
vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TEVA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TEVA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TEVA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
TEVA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TEVA stock moving today?
Why TEVA Stock surged +3.75% Today — RQD Quant Desk Flash. Accounting Warning: Paper earnings outpaced operating cash flow (+153.8% (NI vs OCF)) as receivables rose.